期刊文献+

血管内皮生长因子与子宫内膜透明细胞癌预后相关性研究 被引量:1

The correlated study on VEGF and the prognosis of uterine endometrial dear cell carcinoma
原文传递
导出
摘要 目的研究子宫内膜透明细胞癌ECCC(uterine endometrial clear call carcinoma,ECCC)组织中血管内皮生长因子(vascular endothelial growth factor,VEGF)和血小板源性生长因子(platelet-derived endothelial cell growth factor PD—ECG/TP)的表达,从肿瘤新生血管的形成方面来探讨ECCC的预后相关因素。方法应用免疫组化法检测24例ECCC组织中VEGF、TP的表达,根据VEGF表达情况分成高表达组和低表达组,分析两组患者的生存差异。结果在ECCC组织中,VEGF/TP均有较高的表达,两组患者的生存差异有统计学意义。结论低表达组患者的生存时间长于高表达组。 Objective To determine and analyze the relationship between VEGF/TP expression and ECCC patients'survival time. Methods 24 cases of ECCC were analyzed by immunohistechemistry. We separa- ted the patients into high and Low expressions of VEGF group Results low or high expressions of VEGF and TP has a significant influential difference for the patients' survival time. Conclusion There is a close relationship between VEGF expression and prognosis of ECCC
作者 丁小秋
出处 《中国临床实用医学》 2009年第8期81-82,共2页 China Clinical Practical Medicine
关键词 子宫内膜透明细胞癌 血管内皮生长因子 免疫组化 生存时间 Uterine endometrial clear cell carcinoma Vascular endothelial growth factor Immunohistochemistry Survival time
  • 相关文献

同被引文献22

  • 1詹娜,黎辉,王则胜,熊永炎.子宫内膜透明细胞癌的免疫组化研究[J].诊断病理学杂志,2006,13(2):85-88. 被引量:3
  • 2Mendivil A, Schuler KM, Gehrig PA, et al. Non-Endometrioid Ad-enocarcino-ma of the Uterine Corpus : A Review of Selected Histo-logical Subtypes [J]. Cancer Control, 2009,16 ( 1 ) :46-52.
  • 3Viswanathan AN, Macklin EA, Berkowitz R, et al. The importance of chemotherapy and radiation in uterine papillary serous carcino-ma [J]. Gy- necol Oncol, 2011,123 ( 3 ) : 542-547.
  • 4Oluwole Fadare, MD and Sharon X. Liang, MD, PhDw Diagnostic Utility of Hepatocyte Nuclear Factor 1-Beta Im- munoreactivity in Endometrial Carcino- Lack of Specificity For Endome- trial Clear Cell Carcinoma [J]. Appl Immunohistochem Mol Morphol, 2012; 20(6) :580-587.
  • 5Uwe S, Heidi F, Marco P, et al. Epige- netic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens [J]. BMC Cancer, 2013,13:156.
  • 6Wild P J, Ikenberg K, Fuchs TJ, et al. p53 suppresses type II endometrial car- cinomas in mice and governs endometri- a! tumour aggressiveness in humans [J]. EMBO Mol Med, 2012,4 (8):808- 824.
  • 7Fadare O, Gwin K, Desouki MM, et al. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expres- sion in clear cell carcinoma of the en- dometrium [J]. Mod Pathol, 2013,26 (8): 1101-1110.
  • 8Session DR, Lee GS, Choi J, et al. Expression of cyclin E in gynecologic malignanciesJ [J]. Cynecol oncolo, 1999,72( 1 ) .. 32-37.
  • 9Fadare O, Renshaw IL, Liang SX. Does the Loss of ARID1A (BAF-250a) Expression in Endometrial Clear Cell Carcinomas Have Any Clinicopathologic Significance? A Pilot Assessment [Jl. J Cancer, 2012,3 : 129-136.
  • 10Kawano Y, Kypta R. Secreted antago- nist s of the Wnt signalling pathway [J]. Jcellsci, 2003,116(13) :2627.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部